Investor Relations Dashboard

Mauna Kea Technologies (Euronext: MKEA, FR0010609263; OTCQX: MKEAY), the inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization.

CEO Webcast    JMP Securities 2017 Life Sciences Conference

You can stay up to date on all the latest investor news by signing up to our newsletter  


Latest News

  • July 12, 2017  
    Mauna Kea Technologies highlights new peer-reviewed data supporting use of Cellvizio in the diagnosis of pancreatic cysts
    Read the press release.

  • June 19, 2017  
    New Publication Confirms Benefits of Using Cellvizio for Characterizing Upper Urinary Tract Cancer
    Read the press release.

  • June 14, 2017  
    Mauna Kea Technologies to Present at the JMP Securities 2017 Life Sciences Conference
    Read the press release.

Stock Information

Share Price Information


Click here to view more..




Financial Agenda

  • Jul. 25, 2017 - 2017 First-Half Sales
  • May 3, 2017 - Annual General Meeting
  • Apr. 25, 2017 - 2017 First-Quarter Sales
  • Mar. 23, 2017 - 2016 Full-Year Results



Corporate Governance

The Board of directors of Mauna kea Technologies comprises of an international multi-disciplinary group of experts and industry leaders.